Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of apatinib plus tegafur maintenance therapy in advanced gastric or gastroesophageal junction cancer
ChiCTR1800020061Phase 2Not yet recruiting
- Sponsor
- Baotou Cancer Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and tegafur in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Baotou Cancer Hospital. Primary endpoints: progression-free survival, objective response rate and 1 more. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800020061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020061.